Patients who have signed the informed consent after receiving information about the purpose and method of this study.
Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.
Patients who understand the contents of the survey and can answer the questions directly.
You may not be if
Female patients who are pregnant, have childbearing potential, or are breastfeeding.
Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Clareo Health | A Study of Olanzapine in Participants With Bipolar Disorder.
